The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.
Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.
A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.